Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Severe pulmonary arterial hypertension (PAH) is characterized by clustered proliferation of endothelial cells (ECs) in the lumina of small size pulmonary arteries resulting in concentric obliteration of the lumina and formation of complex vascular structures known as plexiform lesions. This debilitating disease occurs more frequently in women, yet both animal studies in classical models of PAH and limited clinical data suggest protective effects of estrogens: the estrogen paradox in pulmonary hypertension. Little is known about the role of estrogens in PAH, but one line of evidence strongly suggests that the vascular protective effects of 17β-estradiol (estradiol; E2) are mediated largely by its downstream metabolites. Estradiol is metabolized to 2-hydroxyestradiol (2HE) by CYP1A1/CYP1B1, and 2HE is converted to 2-methoxyestradiol (2ME) by catechol-O-methyl transferase. 2ME is extensively metabolized to 2-methoxyestrone, a metabolite that lacks biologic activity, but which may be converted back to 2ME. 2ME has no estrogenic activity, and its effects are mediated by estrogen receptors–independent mechanism(s). Notably, in systemic and pulmonary vascular ECs, smooth muscle cells, and fibroblasts, 2ME exerts stronger antimitotic effects than E2 itself. E2 and 2ME, despite having similar effects on other cardiovascular cells, have opposing effects on ECs; that is, in ECs, E2 is promitogenic, proangiogenic, and antiapoptotic, whereas 2ME is antimitogenic, antiangiogenic, and proapoptotic. This may have significant ramifications in severe PAH that involves uncontrolled proliferation of monoclonal apoptosis-resistant ECs. Based on its cellular effects, 2ME should be expected to attenuate the progression of disease and provide protection in severe PAH. In contrast, E2, due to its mitogenic, angiogenic, and antiapoptotic effects (otherwise desirable in normal quiescent ECs), may even adversely affect endothelial remodeling in PAH, and this may be even more significant if the E2's effects on injured endothelium are not opposed by 2ME (eg, in the event of reduced E2 conversion to 2ME due to hypoxia, inflammation, drugs, environmental factors, or genetic polymorphism of metabolizing enzymes). This review focuses on the effects of estrogens and their metabolites on pulmonary vascular pathobiology and the development of experimental PAH and offers potential explanation for the estrogen paradox in PAH. Furthermore, we propose that unbalanced estradiol metabolism may lead to the development of PAH. Recent animal data and studies in patients with PAH support this concept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,187
HIF-1 and human disease: one highly involved factor
Semenza, G. L. (2000) · Genes & Development · doi:10.1101/gad.14.16.1983 · Cited by 909 · cited 1×
“remodeling, angiogenesis, and cell proliferation.(139) The significance of HIF-1a is evident in (1) severe PAH in humans where HIF-1a is overexpressed in obliterative endothelial lesions(4); (2) MCT-induced and chronic hypoxia–induced PAH, where a similar time-dependent increase in HIF-1a levels correlates with the de…”
BackgroundPulmonary hypertension and inflammation
Tuder, R. M., & Voelkel, N. F. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90020-8 · Cited by 128 · cited 1×
“Inflammation is also considered to be an important component in the pathobiology of various types of human PAH because the mediators of inflammation cause vasoconstriction and inflammatory factors/cells may contribute to vascular remodeling.(98,99) Both the elevated levels of proinflammatory cytokines(100) and the pre…”
Background
Cited by
Sex differences and sex steroids in lung health and disease
Townsend, E. A., Miller, V. M., & Prakash, Y. S. (2012) · Endocrine Reviews · doi:10.1210/er.2010-0031 · Cited by 395
Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute
Hemnes, A. R., Kiely, D. G., Cockrill, B. A., Safdar, Z., Wilson, V. J., Hazmi, M. A., Preston, I. R., MacLean, M. R., & Lahm, T. (2015) · Pulmonary Circulation · doi:10.1086/682230 · Cited by 334
The regulation of adipose tissue health by estrogens
Steiner, B. M., & Berry, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.889923 · Cited by 171
The role of estrogens in the adipose tissue milieu
Bracht, J. R., Vieira‐Potter, V. J., De Souza Santos, R., Öz, O. K., Palmer, B. F., & Clegg, D. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14281 · Cited by 80
Metadata
- Authors
- Tofovic, S. P.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2010-12
- Volume
- 56
- Issue
- 6
- Pages
- 696-708
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2067603961
- Cited by
- 115
- References
- 4
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease. https://app.cochat.ai/papers/10.1097/fjc.0b013e3181f9ea8d
- The paper
- Tofovic, S. P. (2010). Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0b013e3181f9ea8d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.